# A Study of HS-20110 in Participants With Advanced Solid Tumors

> **NCT06892379** · PHASE1 · RECRUITING · sponsor: **Hansoh BioMedical R&D Company** · enrollment: 475 (estimated)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** HS-20110 (Phase Ia：Dose escalation )
- **DRUG:** HS-20110 (Phase Ib:Dose expansion )

## Key facts

- **NCT ID:** NCT06892379
- **Lead sponsor:** Hansoh BioMedical R&D Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-26
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-09-30
- **Target enrollment:** 475 (ESTIMATED)
- **Last updated:** 2026-04-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06892379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06892379, "A Study of HS-20110 in Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06892379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*